Two independent studies published in June 2026 confirm that the 2025–2026 updated COVID-19 vaccine continues to provide meaningful protection against severe disease — even in a population with high prior immunity from both previous vaccines and previous infections.
According to CIDRAP reporting on June 23, 2026, a study of adults who sought healthcare for respiratory illness found that those who had received the 2025–2026 COVID vaccine were 59 percent less likely to develop symptomatic COVID requiring a healthcare visit than those who had not received the updated vaccine, a finding that covers the first two months after vaccination.
A separate study published in JAMA Network Open found adults who received the 2025–2026 vaccine were approximately 55 percent less likely to be hospitalized with COVID-19 and 50 percent less likely to require emergency or urgent care than those who did not receive the updated vaccine.
Why This Matters
Every fall, health care providers, public health officials, and patients face the same question: do this year's updated COVID vaccines still provide meaningful protection? The question is harder to answer than it once was, because most Americans now have high baseline immunity from prior infections, prior vaccinations, or both. Measuring the added benefit of a new vaccine on top of existing immunity requires careful study design.
Both studies addressed this question directly. As the JAMA Network Open study authors wrote: "The findings demonstrate the added benefit of 2025–2026 COVID-19 vaccination irrespective of protection conferred by previous COVID-19 vaccination or SARS-CoV-2 infection." In other words, the booster provided meaningful additional protection above and beyond whatever immunity the participants already had.
What We Know So Far
The first study — which produced the 59 percent finding — was conducted in adults who sought care for acute respiratory illness between September 2025 and January 2026. The study measured whether participants had received the 2025–2026 updated COVID vaccine. Those who had were significantly less likely to test positive for COVID during their medical visit.
CIDRAP noted that the findings align with a separate European study conducted in France, Germany, Ireland, Italy, and Spain by the Vaccine Effectiveness, Burden and Impact Studies primary care group, which found similar results in older adults seeking care for respiratory illness.
The second study — reported by JAMA Network Open and by Gavi's vaccine news coverage — followed adults in the U.S. and found the 2025–2026 vaccine was associated with roughly 55 percent lower hospitalization rates and 50 percent lower emergency or urgent care visit rates compared to unvaccinated individuals.
Context: COVID Risk in Summer 2026
These findings arrive as the CDC has flagged a potential risk of elevated COVID activity this summer, particularly in the South and West. According to the CDC's June 22, 2026 respiratory data update, current COVID activity is low nationally, but the possibility of larger increases remains "if a variant that the immune system no longer recognizes becomes more common."
A heavily mutated variant called BA.3.2 has been detected in more than 30 states. Virologists note its potential to partially evade existing immunity in laboratory studies — though real-world data on severity remain limited. Current vaccines are still expected to provide meaningful protection against severe disease even from new variants.
The protective effect documented in both June 2026 studies was measured against circulating strains. Whether that specific 59 percent and 55 percent protection extends equally against BA.3.2 and any potential successors is unknown, but the studies represent the most current available evidence.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Study 1 type: Observational vaccine effectiveness study (test-negative design) — adults seeking care for acute respiratory illness
- Key finding: 59% reduced risk of symptomatic COVID requiring a healthcare visit (95% CI: 14–83%; wide confidence interval reflects the study size and variance)
- Study 2 type: Observational cohort study — JAMA Network Open
- Key finding: 55% lower hospitalization risk; 50% lower emergency/urgent care visit risk
- What it shows: Added benefit of the 2025–2026 updated vaccine on top of prior immunity
- What it does not prove: Protection against variants circulating after January 2026; specific performance against BA.3.2; durability beyond the study observation period
The wide confidence interval in the 59 percent finding (14 percent to 83 percent) reflects real uncertainty and means the true reduction could be substantially lower or higher than the point estimate. The protection is real, but readers should understand this is a range rather than a precise fixed number.
Who Faces the Greatest Risk Without Updated Vaccination?
The populations who benefit most from updated COVID vaccination include:
- Adults 65 and older, who account for the vast majority of COVID-related hospitalizations and deaths
- People with chronic lung, heart, or kidney disease
- Immunocompromised individuals
- Anyone who has not been vaccinated or had a COVID infection in the past six to 12 months
- Residents of the South and West, where the CDC is flagging potential summer increases
Young, healthy adults without risk factors face a much lower baseline risk of severe COVID and derive proportionally less absolute benefit from vaccination — though they can still transmit the virus to higher-risk contacts.
What You Can Do Now
- If you have not received the 2025–2026 updated COVID vaccine, consider getting it — particularly if you are in a high-risk group or live with someone who is.
- Updated COVID-19 vaccines for the 2026–2027 season are expected in late summer or early fall. High-risk individuals should plan to receive the updated formulation when it is available.
- Monitor the CDC's respiratory data page at CDC.gov/respiratory-viruses for weekly updates on COVID activity in your region.
- If you develop COVID symptoms and are in a high-risk group, contact your physician about antiviral treatment with Paxlovid or Lagevrio — which remains effective against recent circulating variants.
Cost and Access: What Patients Should Know
The 2025–2026 COVID vaccine is available at pharmacies and medical offices nationwide. Under the Affordable Care Act, it is covered at no out-of-pocket cost for most insured patients. For uninsured individuals, community health centers and some pharmacy programs offer the vaccine at reduced or no cost.
What Happens Next
Updated 2026–2027 COVID vaccines are expected to be available in August or September. The FDA and CDC's processes for selecting the vaccine composition are ongoing. The CDC's weekly respiratory surveillance will provide an early warning if COVID activity begins to rise significantly in the South or West. MedicalDaily will report on updated vaccine releases and any changes in COVID activity.
The Bottom Line
Two independent studies published in June 2026 confirm that the updated 2025–2026 COVID vaccine provides meaningful added protection — reducing the risk of needing a doctor visit by approximately 59 percent and the risk of hospitalization by approximately 55 percent. As summer begins and potential seasonal increases loom in the South and West, updated vaccination remains one of the clearest and most available protective steps, especially for people in high-risk groups.
